Research programme: small intestinal cell targeted RNA therapeutics - Nosis Biosciences
Latest Information Update: 10 Sep 2025
At a glance
- Originator Nosis Biosciences
- Class RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 02 Sep 2025 Preclinical trials in Unspecified in USA (unspecified route), prior to September 2025 (Nosis Biosciences pipeline, September 2025)